Strongbridge Biopharma — Investor Presentation (September 2020)
42 slides from Strongbridge Biopharma's investor presentation, Sep 8, 2020
Slide 1: Strongbridge Biopharma plc September 2020
STRONGBRIDGE BIOPHARMA PLC SEPTEMBER 2020
Slide 2: Forward-looking statements
Forward-looking statements This document contains forward‐looking statements relating to the Company’s strategy, objectives, business development plans, financial position, clinical development, regulatory plans and revenue guidance. All statements other than statements of historical facts included
Slide 3: Strongbridge: revenue-generating, rare disease-focused company with potential new product launch
Strongbridge: A revenue-generating, rare disease-focused company with commercial infrastructure and a potential new product launch opportunity 3 Rare disease commercial infrastructure and experience with launching and growing rare disease drugs Development infrastructure to manage global clinical tr
Slide 4: Three-product rare-disease portfolio
Strongbridge has a three-product, rare-disease portfolio 4 Positive results from two Phase 3 studies NDA submission anticipated Q1 2021 10-month PDUFA review expected Launch Q1 2022 if approved Novel, patented, extended release formulation is under evaluation in nonclinical disease models potentiall
Slide 5: Management team experience
Management team experience 5 Robert Lutz Scott Wilhoit Chief Financial Officer Chief Commercial Officer John Johnson Chief Executive Officer • Company Group Chairman, Worldwide Biopharmaceuticals - J&J • CEO - Imclone Systems • President of Global Oncology - Eli Lilly • Multiple Board and Chairman R
Slide 6: RECORLEV (levoketoconazole) in Phase 3 development for Cushing's syndrome
RECORLEV (levoketoconazole) In Phase 3 development for Cushing’s syndrome 6 The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established.
Slide 7: Endogenous Cushing's syndrome is a serious rare disease
Endogenous Cushing’s syndrome is a serious rare disease *According to a retrospective analysis of claims from a large U.S, commercial health plan (885 selected Cushing’s disease cases and 2,655 matched controls without Cushing’s disease) from 2007 to 2011. 7 Affects the whole body Endogenous Cushing
Slide 8: Estimated ~8,000 CS patients in U.S. are Rx-treated
An estimated ~8,000 CS patients in the U.S. are Rx-treated* ~3,200 of whom are not well controlled** Abbreviation: Rx= prescription drug * Source: Secondary literature and company sponsored research ** A07. Of your endogenous Cushing’s patients currently receiving pharmacological therapy, what perce
Slide 9: Levoketoconazole, an enantiomer of ketoconazole, and cortisol inhibition
Levoketoconazole, an enantiomer of ketoconazole, comprises virtually all the cortisol inhibition activity of ketoconazole* *Auchus RJ, Wu JL, Peng HM “2S,4R-Ketoconazole is the Relevant Enantiomer of Ketoconazole for Cortisol Synthesis Inhibition: Steroidogenic P450s Inhibition Involves Multiple Mec
Slide 10: Phase 3 program for Recorlev
Phase 3 program for Recorlev: includes two phase 3 studies with positive results 10 Phase 3 Study Study Design Patients Status SONICS1 Single-arm, open-label, dose-titration study in adults with Cushing’s syndrome (CS) 94 patients enrolled in dose- titration phase • Completed with statistically sign
Slide 11: SONICS phase 3 open-label single-arm study
SONICS, a successfully completed phase 3, multi- center, open-label, single-arm study *1 subject did not enter extended evaluation **mUFC= mean urinary free cortisol 11 94 enrolled in dose titration 77 entered maintenance 61 completed maintenance 46 completed extended evaluation 17 Discontinued 6 ad
Slide 12: SONICS primary endpoint was statistically significant
SONICS primary endpoint was statistically significant *Based on mixed-effects, repeated-measures model with underlying binomial distribution and logit link function, adjusted for baseline covariates. **Abbreviations: ITT= Intent to Treat population; mUFC= mean urinary free cortisol; ***Data based on
Slide 13: Recorlev improved key cardiovascular risk biomarkers in CS
Importantly, Recorlev improved key biomarkers of cardiovascular risk in CS *Hochberg adjustment applied to p-values to control type 1 error †Mean reductions from baseline based on least squares mean changes from repeated- measures model adjusted for baseline covariates 13 Outcome Measure Baseline Me
Slide 14: Summary of key safety findings in SONICS
Summary of key safety findings in SONICS *Includes all alanine aminotransferase (ALT) increases reported as an adverse event regardless of level or relationship to drug. A subset of these ALT increased events was also reported as adverse events of special interest. 14 Most Frequent Treatment-Emergen
Slide 15: LOGICS: phase 3 randomized-withdrawal trial
LOGICS: a phase 3, double-blind, placebo-controlled, randomized-withdrawal trial * Subjects who directly rolled over into LOGICS from SONICS and were on a stable therapeutic dose for 12 weeks prior to screening did not require titration-maintenance ** Early rescue can happen at any time during rando
Slide 16: LOGICS primary endpoint results
The enrolled study population had baseline characteristics comparable to those in the SONICS study, representative of a medically treated CS population with moderate to severe hypercortisolemia LOGICS showed that 54.5% more patients lost response on placebo than on levoketoconazole (p-value: 0.0002)
Slide 17: Cholesterol measures differed between active and placebo
Cholesterol measures showed a significant difference between active and placebo despite a maximum treatment duration of only approximately eight weeks RW1 Phase Baseline Mean Value Mean Change from Baseline at End of RW1 Phase Adjusted p- value2 Outcome Measure L-KTZ Placebo L-KTZ Placebo Fasting Gl
Slide 18: Adverse events in LOGICS comparable to SONICS
Adverse events during levoketoconazole treatment in LOGICS were generally comparable to those seen in SONICS 18 Treatment-Emergent Adverse Events During Levoketoconazole Use (Phases combined) Nausea 29% Hypokalemia 28% Headache 21% Hypertension 19% Diarrhea 15% Treatment-emergent events with inciden
Slide 19: Safety measures in LOGICS comparable to SONICS
Safety measures in LOGICS were generally comparable to those seen in SONICS 19 Liver Test Results During Levoketoconazole Use (Phases combined) (Worst observed value for ALT) ALT > 3x ULN (includes those > 5x ULN) 11.4% ALT > 5x ULN 3.8% Total bilirubin values > 1.5x ULN 0.0% N=79* No Hy’s Law, no t
Slide 20: Recorlev could be launched in U.S. Q1 2022 if approved
Recorlev could be launched in U.S. Q1 2022 if approved 20 NDA submission ~Q1 2021 ~10-month PDUFA review The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established. PDUFA date ~Q4 2021 or Q1 2022 U.S. Launch ~Q1 2022
Slide 21: Recorlev Commercial Opportunity
RECORLEV COMMERCIAL OPPORTUNITY 21 The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established.
Slide 22: U.S. market assessment indicates significant commercial opportunity
U.S. market assessment indicates Recorlev could be a significant commercial opportunity Source: Company sponsored research *Average Number of Endogenous CS Pts w/o Malignant cause in Past Six Months 22 Strongbridge CS Market Assessment CS Market Assessment Summary Qualitative HCP Research − 13 Endoc
Slide 23: Fragmented CS prescribing market dominated by unapproved products
Fragmented CS prescribing market – dominated by unapproved CS products* Source: Company sponsored research Signifor and Signifor LAR are owned by Recordati; Korlym is owned by Corcept * Isturisa was approved on March 9th 2020.after the market research was conducted **2020 Corcept guidance B08. Of yo
Slide 24: Current treatment options have limitations
Current treatment options have limitations Source: Product Labeling 24 Name Target(s) Dosing U.S. Regulatory Status Warnings/Precautions in Label FDA Approved Products - Oral Isturisa (osilodrostat) 11-β-hydroxylase Oral; BID Approved for adult patients with Cushing's disease form whom pituitary sur
Slide 25: A need for new treatment options exists
A need for new treatment options exists Source: Company sponsored research B02. When thinking of your endogenous Cushing’s syndrome patients that you have personally managed in the past six months, please indicate which of the following pharmacological therapies your patients have received. A07. Of
Slide 26: Endocrinologists reacted positively to Recorlev clinical profile
Endocrinologists had a positive reaction to the Recorlev clinical profile and indicated a likelihood to prescribe if approved Source: Company sponsored research D03. Based on this profile, what is your likelihood to prescribe Product Y? Please rate on scale from 1-9, with 1 being “Not at all likely”
Slide 27: 40% of HCPs surveyed do not use ketoconazole
40% of HCPs surveyed do not use ketoconazole Although Ketoconazole is currently the most prescribed treatment, there is a significant opportunity for Recorlev Source: Company sponsored research The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has
Slide 28: Recorlev and ketoconazole profiles
Recorlev and ketoconazole profiles * The data set forth above is not based on directly comparable trials and/or studies ** Source: 1. Young et al. Eur J Endocrinol. 2018 Feb 22. pii: EJE-17-0886. doi: 10.1530/EJE-17-0886. [Epub ahead of print] 28 RECORLEV KETOCONAZOLE Indication Anticipated labeling
Slide 29: Precedent established for CS branded pricing
Precedent established for CS branded pricing* Source: Red Book, Signifor Prescribing Info, Signifor LAR Prescribing Information, Korlym Prescribing Information, Isturisa Prescribing Information * Wholesale/ Acquisition Cost ** Isturisa estimated annual cost based on maintenance dose range of 2mg-7mg
Slide 30: Payers indicated willingness to cover Recorlev across tested price range
Consistent with current branded CS products, Payers indicated a willingness to cover a product like Recorlev throughout the tested price range ($200k-$400k annually) Source: Company sponsored research; *Policy Reporter Commercial Lives, August,, 2020; Excludes Isturisa **Global Peak Sales *** 2020 e
Slide 31: Well defined and efficient endocrinology call point
Well defined and efficient Endocrinology call point 31 25-45 Field facing positions at launch* *Sales Representatives, Patient Access Managers and Medical Science Liaisons COEs and KOLs Ketoconazole prescribing High Volume CS prescribers Community Endos The safety and efficacy of Recorlev (levoketoc
Slide 32: Key imperatives for a successful Recorlev launch
Key imperatives for a successful Recorlev launch 32 Build on Established Strongbridge Commercial Capabilities Recorlev Launch Imperatives Establish Recorlev’s Unique Positioning & Value Proposition Communicate Recorlev’s Anticipated Differentiated Clinical Profile Leverage and Expand KOL and Patient
Slide 33: Potential to capitalize on $2B+ total addressable annual market
Recorlev represents the potential to capitalize on a $2B+ total addressable annual market 33 The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established. ~25,000 ~21,500 ~20,600 Prevalence of Endogenous Cushing’s syndrome in US ~3,20
Slide 34: KEVEYIS (dichlorphenamide)
KEVEYIS (dichlorphenamide) * FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis 34 The first and only FDA-approved therapy for primary periodic paralysis*
Slide 35: Primary periodic paralysis: rare, chronic, genetic neuromuscular disorders
Primary periodic paralysis: a spectrum of rare, chronic, genetic, neuromuscular disorders 35 1. Charles G, Zheng C, Lehmann-Horn F, Jurkatt-Rott, Levitt J. Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. J Neurol. 2013;260:2606-2613. 2. Cannon SC.
Slide 36: Treatment with Keveyis decreased weekly attack rates
4.0 2.0 1.8 1.1 4.8 0.9 2.4 0.3 Study 2 Study 1 Treatment with Keveyis decreased weekly attack rates Keveyis is the first and only FDA-approved product indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants Study 1: Sansone VA, et al. Neurology 20
Slide 37: Keveyis provides revenue and commercial experience
Keveyis provides revenue and commercial experience/expertise for Strongbridge 37 ~4,000 – 5,000* Diagnosed PPP patients in the United States Total addressable market is more than $500M annually We are attempting to extend Keveyis exclusivity by pursuing 12 patent applications 7.0 16.8 21.7 28.0 29.0
Slide 38: IP & Financials
IP & FINANCIALS 38
Slide 39: Intellectual property and orphan exclusivity
Intellectual property and orphan exclusivity Recorlev U.S. Exclusivity: At least 7 years from launch Keveyis U.S. Exclusivity: Expires August 2022 unless extended via IP efforts 39 Orphan Exclusivity EU EU RECORLEV VELDOREOTIDE KEVEYIS Intellectual Property U.S. Method of use: treating Cushing’s syn
Slide 40: 2020 Keveyis revenue guidance and cash position
2020 Keveyis revenue guidance $28M—$29M ~$60M Cash Cash and cash equivalents as of 6/30/20 $30M Debt Facility - $10M drawn at close - Up to $10M more available Q4 2020 based on positive Recorlev data - Up to an additional $10M available upon Recorlev approval and lender consent - No revenue or cash
Slide 41: Near-term key priorities
Near-term key priorities 41 • Submit an NDA for Recorlev to the U.S. FDA Q1 2021 • Launch planning • Achieve our updated full year 2020 guidance range of $28-$29M • Execute on life cycle opportunities underway for KEVEYIS • Manage expenses to achieve or exceed runway guidance of cash lasting through
Slide 42: Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA PLC 42
Strongbridge Biopharma — Investor Presentation (September 2020) on 6ix